EVAXION BIOTECH A/S

(EVAX)
  Report
Delayed Nasdaq  -  03:54 2022-07-06 pm EDT
2.160 USD   -3.14%
07/01Evaxion Biotech A/S Announces That It Is Ready for Recruitment for the Evx-01 Phase 2B Clinical Trial
CI
06/30Evaxion Biotech Announces Gonorrhea as Second Bacterial Product Target
GL
06/30Evaxion Biotech Announces Gonorrhea as Second Bacterial Product Target
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

European ADRs Move Higher in Monday Trading

05/16/2022 | 12:08pm EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
AVADEL PHARMACEUTICALS PLC 1.67% 3.66 Delayed Quote.-54.70%
BIONTECH SE -0.52% 160.2 Delayed Quote.-37.86%
CALLIDITAS THERAPEUTICS AB (PUBL) -3.89% 91.6 Delayed Quote.-15.78%
EDAP TMS S.A. 0.77% 6.55 Delayed Quote.9.35%
ENDAVA PLC -1.08% 89.03 Delayed Quote.-46.98%
EVAXION BIOTECH A/S -3.14% 2.16 Delayed Quote.-51.13%
INTERCONTINENTAL HOTELS GROUP PLC 0.28% 4358 Delayed Quote.-8.89%
NOVO NORDISK A/S -1.09% 799.3 Delayed Quote.9.97%
OPERA LIMITED -3.96% 4.61 Delayed Quote.-34.70%
RYANAIR HOLDINGS PLC 1.76% 11.885 Real-time Quote.-23.41%
SILENCE THERAPEUTICS PLC 27.79% 4.46 Delayed Quote.0.00%
TC BIOPHARM (HOLDINGS) PLC 1.36% 0.3729 End-of-day quote.0.00%
TELECOM ITALIA S.P.A. 0.28% 0.2547 Delayed Quote.-41.50%
VACCITECH PLC 4.06% 4.61 Delayed Quote.-58.51%
VEON LTD. 0.67% 0.448 Delayed Quote.-73.80%
VERONA PHARMA PLC -0.93% 4.26 Delayed Quote.-36.61%
All news about EVAXION BIOTECH A/S
07/01Evaxion Biotech A/S Announces That It Is Ready for Recruitment for the Evx-01 Phase 2B ..
CI
06/30Evaxion Biotech Announces Gonorrhea as Second Bacterial Product Target
GL
06/30Evaxion Biotech Announces Gonorrhea as Second Bacterial Product Target
AQ
06/30Evaxion Biotech A/S Announces Gonorrhea as Second Bacterial Product Target
CI
06/23Evaxion Biotech to Target Non-Small Cell Lung Cancer With Drug Candidate; Shares Rise P..
MT
06/23EVAXION BIOTECH A/S : Expands Its EVX-03 DNA Vaccine Program Into Non-Small Cell Lung Canc..
PU
06/23Evaxion Biotech Expands Its EVX-03 DNA Vaccine Program Into Non-Small Cell Lung Cancer
GL
06/23Evaxion Biotech Expands Its EVX-03 DNA Vaccine Program Into Non-Small Cell Lung Cancer
AQ
06/23Evaxion Biotech Expands its EVX-03 DNA Vaccine Program into Non-Small Cell Lung Cancer
CI
06/10BIOSTOCK : Evaxion Biotech Secures Equity Financing of up to 40 MUSD
AQ
More news
Analyst Recommendations on EVAXION BIOTECH A/S
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -30,0 M - -
Net cash 2022 16,0 M - -
P/E ratio 2022 -1,73x
Yield 2022 -
Capitalization 51,5 M 51,5 M -
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees 61
Free-Float 28,3%
Chart EVAXION BIOTECH A/S
Duration : Period :
Evaxion Biotech A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EVAXION BIOTECH A/S
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 2,16 $
Average target price 15,75 $
Spread / Average Target 629%
EPS Revisions
Managers and Directors
Lars Aage Staal Wegner Chief Executive Officer
Bo Karmark Chief Financial Officer
Marianne Søgaard Chairman
Erik Deichmann Heegaard Chief Medical Officer
Birgitte Rono Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
EVAXION BIOTECH A/S-51.13%51
MODERNA, INC.-37.18%63 467
LONZA GROUP AG-28.02%41 871
IQVIA HOLDINGS INC.-23.44%40 884
SEAGEN INC.13.28%32 237
CELLTRION, INC.-5.81%19 739